泰莫西芬與BP012W乙醇分離物之協同作用造成強化管狀A型乳腺癌細胞凋亡影響

以作者查詢圖書館館藏

、以作者查詢臺灣博碩士

、以作者查詢全國書目

、勘誤回報

、線上人數：65

、訪客IP：18.226.94.206

姓名

鄧棨文(Chi-Wen Deng) 查詢紙本館藏

畢業系所

系統生物與生物資訊研究所

論文名稱

泰莫西芬與BP012W乙醇分離物之協同作用造成強化管狀A型乳腺癌細胞凋亡影響
(Synergy effects of tamoxifen and the ethanol fractions of BP012W to enhance apoptosis of luminal-A breast cancer cells)

相關論文

★ 中草藥BP004誘導管腔A型乳腺癌細胞凋亡	★ 藉由微陣列基因晶片以探討中草藥BP011w對於抑制肺腺癌細胞株爬行及轉移之機制
★ 鑑別可應用在病理與臨床之肺腺癌與鱗狀上皮細胞肺癌的生物標記	★ 中國傳統醫藥蒙古黃耆在HCT116結腸癌細胞體外和體內實驗呈現腫瘤抑制作用
★ 揭示CEP55基因在大腸直腸癌轉移中所扮演的角色	★ BP016W-新型食道鱗狀上皮細胞癌候選藥物
★ 傳統中藥複方FY001W是三陰性乳腺癌新型的候選藥物	★ BP023W在頭頸癌中的細胞毒性與調控機制
★ 藉由L1000?表達圖譜數據來解釋中醫分類方法中的屬性和歸經	★ Solasodine，BP010W成份之一，抑制肺癌的遷移和侵襲能力
★ 蒙古黃耆對大腸癌影響並降低miR-29a的表現量之研究	★ 利用生物資訊策略找出普濟方內加速傷口癒合的新配方
★ 藉助模塊化網路策略尋找普濟方之治療疾病核心配方	★ 探索 BP010W 的治療潛力:基於雌激素信號通路, 以澳洲茄胺作為抑製劑研究肺癌細胞遷移的綜合分析
★ 大數據分析糖尿病患者使用糖尿病藥物後得病因果關係和風險比較以桃園某地區醫院為例

檔案

[Endnote RIS 格式]

[Bibtex 格式]

[相關文章]

[文章引用]

[完整記錄]

[館藏目錄]

[檢視]

[下載]

本電子論文使用權限為同意立即開放。
已達開放權限電子全文僅授權使用者為學術研究之目的，進行個人非營利性質之檢索、閱讀、列印。
請遵守中華民國著作權法之相關規定，切勿任意重製、散佈、改作、轉貼、播送，以免觸法。

摘要(中)

乳癌一直是女性死亡的主要原因，而且死亡人數也是逐年上升。目前最為廣泛使用的化癌藥物，泰莫西芬，作為乳癌的賀爾蒙治療藥物，但若是長期使用容易衍生抗藥性。雖然泰莫西芬效果好，但也會造成像是子宮頸癌和血管栓塞的不良副作用。在中國，傳統中草藥早已用在治療癌症許多年了，其特性相較於化癌藥物，除了毒性較低，也比較少衍生出不好的副作用。本文利用高通量細胞學藥物篩選系統，從60種此類中草藥篩選出蒲公英的萃取物BP012W，BP012W對於管狀A型乳癌細胞株MCF-7表現很強的抑制生長的效果，因此本文我們選擇BP012W做更深入的研究。我們接著用西方墨點法，發現管狀A行乳癌細胞株MCF-7的BAX蛋白質表現量隨著藥物治療而上升，同時Bcl-2的蛋白質表現量則隨之下降。最後我們利用玻璃管柱層析法，將BP012W做藥物分層，依據乙醇濃度變化，0%、20%、40%、60%、80% 和99.9%，並發現只有0% 和20% 仍保持原藥物抑制生長的特性，因此我們將0% 和20% 做合併為EP1，確實發現EP1疊加了0% 和20% 的效果表現最好，最後我們用泰莫西芬做合併治療，發現在管狀A型乳癌細胞株MCF-7，EP1的合併效果比BP012W的合併效果來的好。BP012W和其分成翠取的EP1可能是一個有希望的候選藥物作為乳腺癌治療化療上。

摘要(英)

Breast cancer has been ranked the first leading cause of death among female, and the numbers have been rising over the years. Tamoxifen is the most widely used anti-estrogen for the treatment of breast cancer, but resistance often develops due to long-term use. In addition, adverse side effects including uterine cancer and thromboembolic disease have been attributed to the use of tamoxifen. Traditional Chinese Medicines (TCMs) have been applied for the treatment of cancer in China for many years due to low toxicity and side effects. In this study, we screened 60 TCMs and found that BP012W, one of the families of Asteraceae, showed strong growth inhibition toward luminal-A breast cancer cell line MCF-7, thus was chosen for further studies. The western blot analysis indicated that BAX proteins were increased in expression while BCL-2 was decreased in expression. The DIAION column extraction was performed for isolation of pure compounds from BP012W using different concentrations of ethanol, 0%, 20%, 40%, 60%, 80% and 99.9%, and found that the concentrations at 0% and 20% were most effective in inhibiting proliferation of cells than the crude extract and was denoted EP1. Furthermore, BP012W showed stronger growth inhibition of MCF-7 cells when in combination with tamoxifen than applying tamoxifen alone. BP012W may be a promising candidate as a chemosensitizer for breast cancer treatments.

關鍵字(中)

★ 乳癌
★ 中草藥
★ 泰莫西芬
★ 合併治療

關鍵字(英)

★ Breast cancer
★ Traditional Chinese Medicines
★ Tamoxifen
★ Synergistic anticancer effects

論文目次

中文摘要 i
Abstract ii
Table of contents iii
List of tables v
List of figures vi
List of supplements tables vii
List of supplements figures viii
1. Introduction 1
1-1. Breast cancer 1
1-2. Molecular genetics of breast cancer and targeted therapy 2
2-1. Cell line & drugs 5
2-2. Preparation of BP012W 5
2-3. Preparation active compound fractionation and isolation form BP012W 7
2-4. Cell viability measurement 8
2-5. Analysis of apoptosis by flow cytometry assay 8
2-6. Preparation of protein extracts 9
2-7. Western blot assay 9
2-8. Preparation of RNA extracts 11
2-9. Microarray hybridization 12
2-10. Data analysis 12
2-11. Differential expression analysis 13
2-12. Function and pathway analysis 13
3. Results 14
3-1. In vitro cytotoxicity study by alamar blue assay 14
3-2. Active compound fractionation and Isolation from BP012W 16
3-3. Synergistic anti-proliferative of BP012W and tamoxifen 19
3-3-1. Promotion of tamoxifen-induced apoptosis by BP012W 19
3-3-2. Apoptosis analysis by flow cytometry 21
3-3-3. Differential gene expression and bioinformatics analysis 23
3-4. Bioinformatics analysis 25
3-4-1. Genome-wide expression profiling 25
3-4-2. Data quality assurance 25
3-4-3. Differential expression analysis 26
3-4-4. Function and pathway analysis 27
4. Discussion 38
5. Reference 39
6. Supplements 41
7. Appendix 51

List of tables

Table 1. The extraction of chemical compounds from BP012W using different concentrations of ethanol. 18
Table 2. Quality Assessment of Microarray Gene Expression Data. 26
Table 3. Enriched biological term and biological function analysis of the genes selected as differentially expressed between Tam-treated and untreated MCF-7cells. 28
Table 4. Enriched biological term and biological function analysis of the genes selected as differentially expressed between EP1-treated and untreated MCF-7cells. 29
Table 5. Enriched biological term and biological function analysis of the genes selected as differentially expressed between Tam+EP1-treated and untreated MCF-7cells. 30
Table 6. Enriched biological term and biological function analysis of the genes selected as differentially expressed between EP2-treated and untreated MCF-7cells. 31
Table 7. Enriched biological term and biological function analysis of the genes selected as differentially expressed between Tam+EP2-treated and untreated MCF-7cells. 32

List of figures

Figure 1. A detailed extraction procedure for TCM was established. Water-soluble compounds for BP012 was extracted by condenser. 6
Figure 2. Active compound fractionation and Isolation form BP012W. 7
Figure 3. The different effectivenesses of BP012W on suppressing breast cancer subtypes. 15
Figure 4. Effect of crude BP012W and its ethanol extracts on the viability of MCF-7 cells. 17
Figure 5. Enhancement of tamoxifen-induced apoptosis in breast cancer cell lines by BP012W and isolated compounds. 20
Figure 6. Promotion of tamoxifen-induced apoptosis by BP012W and EP1. 22
Figure 7. Western blot analysis of BP012W and EP1 treated alone or combination with tamoxifen for 72 hrs. 24
Figure 8. Functional analysis for MAPK and APK expression levels in different treatment on MCF-7 cell lines. 33
Figure 9. Function analysis for expression of TGF-β to inhibit tumorigenesis while treatment with Tam+EP1. 34
Figure 10. Function analysis for negative regulation of SMAD protein complex assembly switching off the biological response. 35
Figure 11. Function analysis for overexpressing immune response genes had better prognosis. 36
Figure 12. Apoptosis pathway from KEGG pathway. 37

List of supplements tables

Table S1. Estimated New Female Breast Cancer Cases and Deaths by Age, US, 2015*. 41
Table S2. Experiment buffer reagents for drugs screening. 42
Table S3. Molecular subtpyes of breast cancer and systemic treatment recommendations for subtypes. 43
Table S4. RNA QA/QC information. 44
Table S5. Quality control by Expression Console™ 1.3.1.187 45
Table S6. Complete summary table of functional analysis 51

List of supplements figures

Figure S1. That is RNA quality information for array analysis. 41
Figure S2. Effect of crude BP004W and its methanol extracts on the viability of MCF-7 cells. 47
Figure S3. Isolation from BP012W by separatory funnel with organic solvents. 43
Figure S4. Tam-R cells were derived by long-term exposure to tamoxifen and grown under the same conditions as wild-type MCF-7 cells. 49
Figure S5. Western blot analysis of tamoxifen treated alone or combination with ethanol extracts form BP012W for 72 hrs. 50

參考文獻

1. Siegel, R.L., K.D. Miller, and A. Jemal, Cancer statistics, 2015. CA: a cancer journal for clinicians, 2015. 65(1): p. 5-29.
2. SEER Stat Fact Sheets: Female Breast Cancer. National Cancer Institute 2013; Available from: http://seer.cancer.gov/statfacts/html/breast.html.
3. Breast Cancer Facts & Figures 2015-2016. American Cancer Society, 2015.
4. 衛生福利部國民健康屬. 民國103年主要死因統計結果分析. 2014; Available from: http://www.hpa.gov.tw/BHPNet/web/HealthTopic/TopicArticle.aspx?No=201312230001&parentid=200712250033.
5. Sotiriou, C. and L. Pusztai, Gene-expression signatures in breast cancer. New England Journal of Medicine, 2009. 360(8): p. 790-800.
6. Van′t Veer, L.J., et al., Gene expression profiling predicts clinical outcome of breast cancer. nature, 2002. 415(6871): p. 530-536.
7. Hu, Z., et al., The molecular portraits of breast tumors are conserved across microarray platforms. BMC genomics, 2006. 7(1): p. 96.
8. Perou, C.M., et al., Molecular portraits of human breast tumours. Nature, 2000. 406(6797): p. 747-752.
9. Sørlie, T., et al., Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proceedings of the National Academy of Sciences, 2001. 98(19): p. 10869-10874.
10. Sørlie, T., et al., Repeated observation of breast tumor subtypes in independent gene expression data sets. Proceedings of the National Academy of Sciences, 2003. 100(14): p. 8418-8423.
11. Sotiriou, C., et al., Breast cancer classification and prognosis based on gene expression profiles from a population-based study. Proceedings of the National Academy of Sciences, 2003. 100(18): p. 10393-10398.
12. Goldhirsch, A., et al., Meeting highlights: international consensus panel on the treatment of primary breast cancer. Journal of Clinical Oncology, 2001. 19(18): p. 3817-3827.
13. Holliday, D.L. and V. Speirs, Choosing the right cell line for breast cancer research. Breast Cancer Research, 2011. 13(4): p. 1.
14. Chen, M.H., et al., Impact of respiratory maneuvers on cardiac volume within left-breast radiation portals. Circulation, 1997. 96(10): p. 3269-3272.
15. Hurtado, A., et al., Regulation of ERBB2 by oestrogen receptor–PAX2 determines response to tamoxifen. Nature, 2008. 456(7222): p. 663-666.
16. Gallo, M.A. and D. Kaufman. Antagonistic and agonistic effects of tamoxifen: significance in human cancer. in Seminars in oncology. 1997.
17. S, G., Tamoxifen (TAM): the dispute goes on, in ANN IST SUPER SANITÀ2006.
18. Tamoxifen for Breast Cancer & Side Effects. 2009; Available from: http://healthlifeandstuff.com/breast-cancer/tamoxifen-for-breast-cancer-side-effects/.
19. Known and Probable Human Carcinogens. 2006-02-03; Available from: http://www.cancer.org/cancer/cancercauses/othercarcinogens/generalinformationaboutcarcinogens/known-and-probable-human-carcinogens?sitearea=PED.
20. Chen, X.-W., K. B Sneed, and S.-F. Zhou, Pharmacokinetic profiles of anticancer herbal medicines in humans and the clinical implications. Current medicinal chemistry, 2011. 18(21): p. 3190-3210.
21. Huang, D.W., B.T. Sherman, and R.A. Lempicki, Bioinformatics enrichment tools: paths toward the comprehensive functional analysis of large gene lists. Nucleic acids research, 2009. 37(1): p. 1-13.
22. Huang, D.W., B.T. Sherman, and R.A. Lempicki, Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nature protocols, 2009. 4(1): p. 44-57.
23. Fu, X., et al., Overcoming endocrine resistance due to reduced PTEN levels in estrogen receptor-positive breast cancer by co-targeting mammalian target of rapamycin, protein kinase B, or mitogen-activated protein kinase kinase. Breast Cancer Research, 2014. 16(5): p. 1.
24. Lin, H.Y., et al., Expression cloning of the TGF-β type II receptor, a functional transmembrane serine/threonine kinase. Cell, 1992. 68(4): p. 775-785.
25. Wakefield, L.M., E. Piek, and E.P. Böttinger, TGF-β signaling in mammary gland development and tumorigenesis. Journal of mammary gland biology and neoplasia, 2001. 6(1): p. 67-82.
26. Teschendorff, A.E., et al., An immune response gene expression module identifies a good prognosis subtype in estrogen receptor negative breast cancer. Genome biology, 2007. 8(8): p. 1.
27. Schmidt, M., et al., The humoral immune system has a key prognostic impact in node-negative breast cancer. Cancer research, 2008. 68(13): p. 5405-5413.

指導教授

蘇立仁(Li-Jen Su)

審核日期

2016-7-27

推文